Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068

Antiviral Therapy

Volumn 1, Issue 2, 1996, Pages 77-88

  Mildvan, Donna ^a   Bassiakos, Yiannis ^b,o   Zucker, Marcia L ^c,p   Hyslop Jr , Newton ^d   Krown, Susan E ^e   Sacks, Henry S ^c   Zachary, James ^d   Paredes, Josephine ^e   Fessel, W Jeffrey ^f   Rhame, Frank ^g   Kramer, Francoise ^h   Fischl, Margaret A ⁱ   Poiesz, Bernard ^j   Wood, Kenneth ^b   Ruprecht, Ruth M ^k   Kim, John ^k,q   Grossberg, Sidney E ^l   Kasdan, Patricia ^m   Bergé, Peter ^a   Marshak, Ann ^a   Pettinelli, Carla ⁿ   more..

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f KAISER FOUNDATION HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j STATE UNIVERSITY OF NEW YORK   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l MEDICAL COLLEGE OF WISCONSIN   (United States)

^m Pediatric ACTG Operations Center   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^p International Technidyne Corporation   (United States)

^q STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; GAG PROTEIN; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG POTENTIATION; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRADERMAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; ZIDOVUDINE;

EID: 17144467145     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy D, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L & The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England Journal of Medicine 1990; 322:941-949.
2. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy D, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA, Volberding PA, Pettinelli C, Anderson J & The AIDS Clinical Trials Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Annals of Internal Medicine 1990; 112:727-737.
3. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, Kind D & The AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. New England Journal of Medicine 1987; 317:185-191.
4. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, Hawkes CA, Jensen PC, Klimas NG, Labriola AM, Laharat CJ, O'Brien WA, Oster CN, Weinhold KJ, Wray NP, Zolla-Pazner SB & The Veterans Affairs Cooperative Study Group on AIDS Treatment. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. New England Journal of Medicine 1992; 326:437-443.
5. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:871-881.
6. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT, Fischl MA, Soeiro R for the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cells counts of 500 or more per cubic millimeter. New England Journal of Medicine 1995; 333:401-407.
7. Borden EC & Fall LA. Interferons: biochemical, cell growth, inhibitory and immunologic effects. Progress in Hematology 1981; 350:1-64.
8. Krown SE. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semininars in Oncology 1987; 14(Suppl. 3):27-33.
9. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT Jr, Falloon J, Polis MA, Salzman NP, Baseler M, Masur H & Fauci AS. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 1990; 112:805-811.
10. DeStefano E, Friedman RM, Friedman-Kien AE, Goedert JJ, Henriksen D, Treble OT, Sonnabend JA & Vilcek J. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. Journal of Infectious Diseases 1982; 146:451-455.
11. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT & Hirsch MS. Recombinant interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1985; i:602-604.
12. Shirzai Y & Pitha PM. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. Journal of Virology 1992; 66:1321-1328.
13. Poli G, Orenstein JM, Kinter A, Folks TM & Fauci AS. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989; 244:575-577.
14. Francis ML, Meltzer MS & Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Research & Human Retroviruses 1992; 8:199-207.
15. Meylan PRA, Guatelli JC, Munis JR, Richman DD & Kornbluth RS. Mechanisms for the inhibition of HIV replication by interferons-α, -β and -γ in primary human macrophages. Virology 1993; 193:138-148.
16. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H & Barry DW. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1986; 83:8333-8337.
17. Yarchoan R, Mitsuya H, Myers CE & Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. New England Journal of Medicine 1989; 321:726-738.
18. Hartshorn KL, Vogt MW, Chou T-C, Blumberg RS, Byington R, Schooley RT & Hirsch MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrobial Agents & Chemotherapy 1987; 31:168-172.
19. Johnson VA, Barlow MA, Merrill DP, Chou T-C & Hirsch MS. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. Journal of Infections Diseases 1990; 161:1059-67.
20. Ruprecht RM, Chou T, Chipty F, Sosa MG, Mullaney S, O'Brien L & Rosas D. Interferon-α and 3′-azido-3′-deoxy thymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. Journal of Acquired Immune Deficiency Syndromes 1990; 3:591-600.
21. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, Metcalf JA, Bigley J, Sawyer LA, Zoon KC, Masur H, Fauci AS & Lane HC. Combined zidovudine and interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Annals of Internal Medicine 1989; 111:280-287.
22. Krown SE, Gold JWM, Niedzwiecki, D. Bundow D, Flomenberg N, Gansbacher B & Brew BJ. Interferon-α with zidovudine: safety, tolerance and clinical virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 1990; 112:812-821.
23. Fischl MA, Uttamachandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-Reese J, Dearmas L, Chidekel J, McCann M & Myers M. A phase I study of recombinant human interferon-α2a or human lymphoblastoid interferon-αn1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. journal of Acquired Immune Deficiency Syndromes 1991; 4:1-10.
24. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, Manischewitz J, Quinnan G, Masur H & Fauci AS. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2:1218-1223.
25. De Witt R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH & Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988; 2:1214-1217.
26. Mildvan D, Ruprecht R, Krown S & Pettinelli C. Application of the combination index method in the design of a clinical antiretroviral trial: ACTG 068 Journal of Acquired Immune Deficiency Syndromes 1990; 3(Suppl. 2):S111-S113.
27. Mildvan D & The ACTG 068 Collaborative Group. A Phase I/II open-label trial to evaluate the antiviral potential of combination low dose zidovudine (ZDV) and interferon-α-2A in patients with symptomatic HIV disease. VII International Conference on AIDS, Florence, Italy, 16-21 June 1991. Abstract TH.B.34.
28. Mildvan D, Bassiakos Y & The ACTG 068 Collaborative Group. Zidovudine (ZDV) and interferon-α-2A (IFN): ongoing assessment of synergy and tolerance in early ARC patients, ACTG 068. VIII International Conference on AIDS, Amsterdam, The Netherlands, 19-24 July 1992. Abstract PoB 3586.
29. Zucker ML, Huberman KT, Hirschman SZ, Mildvan D & The ACTG 068 Collaborative Group. Long term stability of HIV-1 p24 antigen upon storage at -70°C. VIII International Conference on AIDS, Amsterdam, The Netherlands, 19-24 July 1992. Abstract PuA 6203.